Stage 4 Breast Cancer Treatment
Overcoming Late-Stage Breast Cancer with the Latest in Medical Advances
Breast cancer affects hundreds of millions of lives, both directly and indirectly every year. All the mothers, daughters, and sisters who have fought against this disease hold a special place in the hearts of ICCA and its staff. Every single one of these brave women is unique and their cancer treatment needs to be as unique as they are, one-of-a-kind. At ICCA, we are a center of excellence for personalized oncology and we go beyond standardized treatment protocols by offering genetically customized and personally targeted treatments including immunotherapy, chemotherapy, and natural therapy options. Our methods are a unique approach to breast cancer treatment that utilizes the most advanced genetic and environmental testing to build next-level personalized breast cancer treatment plans. We establish a true medical blueprint for you and use it to integrate a treatment plan uniquely suited to give you the best chance to improve your outcome.
Integrative Cancer Centers of America specializes in the treatment of persistent and late-stage breast cancer and has been doing so for nearly two decades with no sign of slowing down. While an early diagnosis of breast cancer can result in a successful remission, all too often these patients are not properly diagnosed early enough, and the possible spread of their cancer is not screened for, resulting in recurrence after successful treatment. Circulating tumor cells and free-floating DNA are difficult to recognize when they are not being looked for. When they are missed, trying to achieve lasting results is almost impossible. Many of our patients discover ICCA after their current standardized approach to breast cancer has failed to yield lasting results. Fortunately, this is where ICCA puts its focus, on undoing the damage standardized treatment protocols can have on the body while helping our patients achieve a better response to care through the use of the latest innovations in breast cancer treatment options. We excel at recognizing circulating tumor cells and free-floating DNA, giving us the upper hand at identifying and treating metastasized breast cancer.
Most of the patients who find their way to ICCA have experienced an approach to care that was focused on managing the disease as opposed to treating the source. New drugs may offer genetic driven therapy and immunotherapy options but fail to address the root cause of metastasized breast cancer. We have been successful at helping our patients respond more favorably to treatment after they have exhausted all standardized medical options because we break away from the "cookie-cutter" approach to care and truly look at the patient as an individual and not just a diagnosis.
Most breast cancer treatment consists of the NCCN's one-size-fit-all protocol that uses the same old combination of surgery, radiation, chemotherapy, and hormone blockers followed up with clinical trials and hospice. This method is taxing and invasive with many potential side-effects yielding sporadic results. Because of our truly integrative approach, we are not bound by the structure approved by the NCCN and can use the latest treatment options from around the world to help attack your breast cancer.
At ICCA we use cutting-edge, proprietary oncology designed with genetically-targeted chemotherapies that can precisely attack your breast cancer while reducing the worst side-effects on your body. We combine this with a multitude of integrative treatments from around the world to build a multifaceted treatment protocol targeted towards fighting your breast cancer and the root causes of your condition. We attack your cancer from all angles, utilizing a personalized combination of immunotherapies, detoxification methods, patient specific chemotherapies, and genetic therapies created and combined in ICCA's own in-house pharmacy to ensure the treatments delivered to you are of the highest quality.
ICCA would not be able to provide the comprehensive in-depth care it has established without the help of Vertisis, our in-house custom pharmacy. All the medications including natural medicines, chemotherapies, and immunotherapies are custom prepared in our pharmacy and are built specifically for our patients' genetic needs. This relationship turns the future of customized personal medicine to a reality of today. Other clinics may say they use genetic targeting for their treatment but they are limited to what medications are commercially available; where at Vertisis our team is able to customize medications based on your specific needs which makes ICCA a truly unique and cutting-edge cancer clinic.
During our 20 years of treating cancer and chronic disease, Integrative Cancer Centers of America has been pioneering the use of personalized cancer care to treat patients who have exhausted their standardized cancer treatment options. Many of our patients leave our care wishing they had found us earlier. Our experience in the integrative cancer field is unmatched, and we understand that breast cancer is a disease of genetic mutations, biomarkers, and molecular profiles. Women who have at least one relative who has had breast cancer are almost twice as likely to develop breast cancer, and gene mutations like BRCA 1 & 2 are identified and used by ICCA to build your breast cancer treatment . However, 85% of breast cancer cases are not the result of inherited genetic mutation . This builds a complicated landscape when trying to treat breast cancer and being able to identify the genetic factors of your breast cancer; whether they are inherited, environmental or both is immensely important when taking the proper course to treat your breast cancer. Our proprietary genetic testing is, by design, more in-depth than most clinics in the nation, and it can identify genetic mutations that are causing and facilitating your breast cancer's growth and potential to spread. We use this information to help form your true medical blueprint and hit your unique breast cancer treatment targets while strengthening and detoxing your immune system and body.
Establishing your true medical blueprint is the first step towards taking a personalized approach to your breast cancer treatment and, especially for breast cancer, genetic factors are an important part of that blueprint. ICCA is pioneering the use of epigenetic targets to turn off tumor-causing oncogenes and turn on tumor suppressant genes. Our ability to identify, track, and modulate the genetic factors of your cancer is second to none. We utilize the latest technology and have the experience to properly identify these genetic factors to help promote better outcomes. Our goal is to give our patients the best chance to respond favorably to care, and we will continue to stay on the cutting-edge of medicine to achieve that goal.
We want to provide the highest quality care to our patients. That is why we personalize all our treatments and custom-make all our medications in our in-house pharmacy. Instead of using massive clinical trials based on cancer type and stage to determine what chemotherapy to use, we gather biomarker information on your circulating cancer cells and test them to see what chemotherapies work best against your personal strain of cancer. Your circulating cancer cells can be taken easily from your blood and, unlike biopsied tumors, they represent the most current mutations of your cancer and give the most recent biomarker information. We find and target more biomarkers than standardized treatment protocols because we can utilize more chemotherapies at one time than what is possible with other oncology methods . Standardized protocol calls for a maximum therapeutic dose when administering chemotherapy because absorption of the drugs into cancerous cells is poor. At Integrative Cancer Centers of America our goal is to get 100% cancer cell absorption. Through therapeutic methods, we increase the amount of chemo-medication being absorbed into cancerous cells, allowing us to provide a unique approach to chemotherapy. We can significantly decrease the dose of chemotherapy while increasing the number of chemo-agents being used and the frequency of administration . This leads to focused chemotherapy that hits more biomarkers while decreasing the negative side-effects on the patient's body. We call this treatment Genetically Targeted Fractionated Chemotherapy and we believe it is the future of chemotherapy.
We developed Genetically Targeted Fractionated Chemotherapy (GTFC) to provide a more effective form of care while reducing the major side-effects on our patients. GTFC uses genetic information to find chemotherapies that are best suited to attack your cancer, this is in stark opposition to the NCCN guidelines that require doctors to use specified chemotherapies based on condition instead of personalized genetic information. We draw circulating cancer cells from your blood and determine the best chemotherapies to treat your personal cancer. We then use natural medicine and therapies to influence your cancer cells into absorbing the chemotherapy and assist your body and immune system in recovering. Finally, we use our in-house custom pharmacy to build the medications designed to address our patients' genetic mutations.
The GTFC method allows us to use targeted chemotherapies at an increased frequency while utilizing smaller doses . This treatment method helps increase the effectiveness of chemotherapy while simultaneously reducing the negative side-effects . GTFC has also proven to be successful at combating cancer that has become resistant to treatment and is used in combination with other ancillary treatments and methods including immunotherapy that may help treat resistant forms of cancer. We are very experienced with treating multi-drug resistant cancers and have done extensive research in to the mechanisms that cancer cells use to pump chemo out of its cells and other factors that create a resistant form of cancer. We aim to disable these pumps, reducing the cancer's ability to fight against treatment while treating the root causes of your breast cancer, providing the best possible chance for our patients.
The CIPI ™ Procedure: Low Dose Chemoembolization
In addition to GTFC, ICCA has developed a form of precision tumor chemoembolization that is designed to treat inoperable tumors that are fibrous and difficult to penetrate through traditional intravenous chemotherapy means. CIPI ™, or Chemo Immunotherapy Percutaneous Injections is a unique form of tumor chemoembolization that utilizes ICCA's advanced world-class testing and meticulous genetic targeting to directly impact large tumor sites. This exciting new therapy could revolutionize the treatment of breast cancer by diligently targeting hard to reach sites of metastasis like bone, lung, and liver.
CIPI ™ has the potential to increase medication delivery and maximize bioavailability by utilizing direct injection of genetically personalized micro-dosed medications into the tumor. This can result in increased tumor kill while potentially reducing the debilitating side-effects normally associated with aggressive chemotherapies. ICCA's Chemo Immunotherapy Percutaneous Injections are a revolutionary new alternative option for patients suffering from advanced breast cancer prognoses where traditional IV chemotherapy is not an optimal option.
There is no stone left unturned when you come to ICCA, we utilize the world's most effective and research-based medical therapies to treat your breast cancer at its source. When you come to ICCA we will work to find the best possible combination of these treatments based on your unique condition and attack your breast cancer from all angles. If you are looking for a better approach to breast cancer treatment for you or a loved one, please contact our Patient Care Coordinators at (888) 526-6398. They are trained professionals and will be happy to answer any questions you have. May God bless you on your journey to healing!
 Cancer.org, B. U.S. Breast Cancer Statistics. 2018 12/20/18 [cited 2019 01/03]; Available from: https://www.breastcancer.org/
 Smith, A.J., J. Oertle, and D. Prato, Genetically Targeted Fractionated Chemotherapy. Journal of Cancer Therapy, 2015. Vol.06No.02: p. 17.